Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Signs Three New Customers for Gateway Tech, Clones

NEW YORK, Sept. 30 (GenomeWeb News) - Invitrogen yesterday said it will supply Gateway technology and clones to three genomic research centers in the United States, Germany, and the United Kingdom.

Terms of the licensing agreements call for the company to offer the platform to Open Biosystems, a US-based distributor of genomic and proteomic research products; the UK Medical Research Council, a UK government-funded medical-research organization; and Ressourcenzentrum fur Genomforschung, a nonprofit German service center for genomics and proteomics research.

 

Invitrogen's Gateway technology enables researchers to insert a single entry clone into as many expression vectors as needed to study its function in a variety of ways, according to a company statement.

 

Invitrogen said additional licensing agreements will be announced in the coming weeks. Financial terms of the agreements were not disclosed.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.